Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OBI 833

Next Previous
Drug Profile

OBI 833

Alternative Names: Globo H-CRM 197; OBI-833; OBI-833/OBI-821

Latest Information Update: 17 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Academia Sinica
  • Developer OBI Pharma
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 08 Jul 2024 Chang Gung Memorial Hospital plans a phase I trial for Cholangiocarcinoma (Late-stage disease, Metastatic disease, unresectable/inoperable, Second-line therapy or greater) in Taiwan (SC, Injection) (NCT06490198)
  • 31 May 2024 Efficacy data from the phase II trial in Non-small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Pharmacodynamics data from preclinical studies in Non-small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top